Answers are grounded in this paper and cite their sources.
OBJECTIVES/BACKGROUND: Our objectives were to evaluate treatment persistence, effectiveness, safety, treatment sequencing patterns, and factors associated with treatment response in a real-world cohort of patients with resistant migraine receiving calcitonin gene-related peptide (CGRP)-targeted therapies. Real-world evidence on CGRP-targeted therapies has primarily focused on anti-CGRP monoclonal antibodies, whereas data regarding gepants, treatment sequencing, and determinants of treatment success remain limited. Understanding outcomes across therapeutic lines is increasingly relevant as switching between CGRP-targeted therapies becomes common in clinical practice. METHODS: We conducted a single-center retrospective cohort study in a tertiary hospital between June 2020 and June 2026, including adults with resistant migraine treated with anti-CGRP monoclonal antibodies (erenumab, fremanezumab, or galcanezumab) or gepants (atogepant or rimegepant). The primary end point was treatment persistence. Secondary end points included effectiveness, safety, treatment sequencing patterns, and factors associated with treatment response. Effectiveness was defined as achievement of a ≥50% reduction in monthly migraine days (≥50% responders) at 6 and 12 months. Safety was assessed through adverse events reported during treatment. RESULTS: A total of 254 patients contributed 312 treatment episodes, including 254 first-line and 58 greater than or equal to second-line CGRP-targeted treatment episodes. Treatment persistence was significantly higher among first-line than greater than or equal to second-line treatment episodes, with 12-month persistence rates of 78.4% (95% confidence interval [CI] = 73.4-83.7) and 44.4% (95% CI = 32.1-61.2), respectively. In multivariable analyses, greater than or equal to second-line treatment was independently associated with a higher hazard of treatment discontinuation (adjusted hazard ratio = 2.84, 95% CI = 1.73-4.66; p < 0.001). At 6 months, ≥50% responder rates were significantly higher in first-line treatment episodes than greater than or equal to second-line treatment episodes (133/220 [60.5%] vs. 10/34 [29.4%]; p < 0.001). No significant differences in persistence or effectiveness were observed between therapeutic classes or individual CGRP-targeted therapies. High-frequency episodic migraine was independently associated with higher odds of treatment response (adjusted odds ratio = 2.53, 95% CI = 1.12-5.70; p = 0.026), whereas treatment with gepants, higher baseline Migraine Disability Assessment scores, two or more migraine-related comorbidities, concomitant onabotulinumtoxinA use, and concomitant use of other oral preventive treatments were associated with lower odds of response. Adverse events occurred in 33.2% of treatment episodes and were predominantly mild; only two grade≥3 adverse events were reported. Treatment discontinuation due to adverse events occurred in 12.5% of treatment episodes. CONCLUSION: CGRP-targeted therapies demonstrated favorable persistence, effectiveness, and tolerability in resistant migraine. Treatment line emerged as a major determinant of outcomes, with superior persistence and effectiveness observed in first-line therapies. Nevertheless, clinically meaningful benefit was still observed in a substantial proportion of later-line treatment episodes, suggesting that some patients may derive benefit from switching between CGRP-targeted therapies in contemporary migraine practice.
No takes yet. Share an insight, caveat, or question.
Pons-Fuster et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: